Share: Axcella Health Inc (NASDAQ: AXLA) is a clinical-stage biotechnology company focused on endogenous metabolic modulators, or EEMs, said Axcella Health CEO Bill Hinshaw Thursday on Benzinga's YouTube show "Power Hour." Axcella Health has two "rapidly progressing" Phase II late-stage clinical development programs, he said. The company earlier announced Phase II clinical trials for its drug to treat nonalcoholic steatohepatitis, or NASH, which the CEO explained as a complex fatty liver disease, adding that more than 40 million Americans have it. Hinshaw told Benzinga that NASH will be an $8 billion-plus market by 2027 and the company expects to be one of the leaders in the treatment of NASH.